RxSight (NASDAQ:RXST) Price Target Raised to $9.00 at UBS Group

RxSight (NASDAQ:RXST) had its target price upped by UBS Group from $8.00 to $9.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other analysts have also recently weighed in on RXST. William Blair initiated coverage on RxSight in a research report on Friday, January 30th. They issued a “market perform” rating for the company. Wolfe Research upgraded RxSight to an “outperform” rating in a report on Friday, January 30th. JPMorgan Chase & Co. increased their price target on RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Thursday, November 6th. Piper Sandler reduced their price objective on shares of RxSight from $11.00 to $10.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Wells Fargo & Company upped their price objective on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Thursday, November 6th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $9.89.

RxSight Stock Down 10.1%

Shares of RXST opened at $7.92 on Thursday. The firm has a market cap of $325.67 million, a price-to-earnings ratio of -8.34 and a beta of 1.14. The company’s fifty day moving average is $9.44 and its 200-day moving average is $9.48. RxSight has a 12 month low of $6.32 and a 12 month high of $29.69.

Hedge Funds Weigh In On RxSight

Several large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in RxSight in the 2nd quarter valued at $28,000. Bessemer Group Inc. acquired a new position in shares of RxSight during the second quarter valued at about $33,000. Larson Financial Group LLC lifted its stake in shares of RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after buying an additional 3,063 shares during the period. Finally, CWM LLC grew its position in RxSight by 211.1% during the fourth quarter. CWM LLC now owns 3,826 shares of the company’s stock worth $40,000 after buying an additional 2,596 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight News Roundup

Here are the key news stories impacting RxSight this week:

• Positive Sentiment: Q4 results beat expectations: RxSight reported GAAP EPS of ($0.03) vs. the consensus loss of ($0.25) and revenue of $32.61M roughly in line with estimates — an earnings beat that limits downside. Zacks: Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: UBS raised its price target from $8 to $9 while keeping a neutral rating, showing modest analyst support for upside from current levels. Benzinga: UBS Raises PT
• Neutral Sentiment: Piper Sandler lowered its target from $11 to $10 but maintained a neutral rating — a mixed signal that modestly reduces implied upside. Benzinga: Piper Sandler Lowers PT
• Neutral Sentiment: Company posted Q4/2025 earnings call transcripts and additional disclosures (useful for detail but not a directional catalyst by itself). Yahoo: Q4 2025 Earnings Call Transcript Seeking Alpha: Transcript
• Negative Sentiment: FY‑2026 revenue guidance came in at $120M–$135M versus a Street consensus near $135.4M — a guide that sits at or below expectations and is the primary near‑term negative catalyst. Business Insider: Q4 & 2026 Guidance
• Negative Sentiment: Revenue is down ~18.9% year‑over‑year and the company reported negative margins and ROE — signs of operating pressure that could weigh on valuation until growth stabilizes. MarketBeat: Earnings Summary
• Negative Sentiment: Short interest rose materially in February to ~14.4% of shares outstanding (days-to-cover ~4.7), increasing downside selling pressure and volatility risk — though it also raises short‑squeeze potential.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.